Lyell Immunopharma promotes Stephen Hill to COO effective Nov 1, 2021

Lyell Immunopharma, Inc.

Stephen Hill promoted from Chief Technical Operations Officer to Chief Operating Officer, effective November 1, 2021.
Hill joined Lyell in June 2019; prior roles include SVP at AstraZeneca and VP at Amgen.
New base salary of $485,000 with an annual bonus target of up to 55% of base salary.
No family relationships with directors or executive officers; no arrangements with other persons.
Employment is at-will; successor not appointed; no departure of any other officer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Stephen Hill

Chief Operating Officer

LYEL · Lyell Immunopharma, Inc.

Effective: 2021-11-01
Filed: October 28, 2021, 7:59 PM ET

On October 23, 2021, the compensation committee (the “Compensation Committee) of the board of directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) approved the promotion of Stephen Hill, the Company’s Chief Technical Operations Officer, to the position of Chief Operating Officer, to serve in such position until his successor is appointed or until his earlier resignation or removal. Such promotion will be effective on November 1, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Hill changed role as Chief Operating Officer at Lyell Immunopharma, Inc..

Action: promoted
Role: Chief Operating Officer

Exact text from the filing

On October 23, 2021, the compensation committee (the “Compensation Committee) of the board of directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) approved the promotion of Stephen Hill, the Company’s Chief Technical Operations Officer, to the position of Chief Operating Officer, to serve in such position until his successor is appointed or until his earlier resignation or removal. Such promotion will be effective on November 1, 2021.

View on SEC.gov

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-309692

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.